Recent studies revealed that mutant p53 has binding partners, including NF-Y, ETS1, ETS2, p73, and p63, and it gains new oncogenic activities in tumor cells through interactions with these binding proteins9–11. The gene discussed is TP53; the disease is neoplasm.